Biotechnology

Apellis Pharma

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Biogen plans to acquire Apellis

Biogen to acquire Apellis Pharmaceuticals for $41 per share

Apellis Pharma released FY2025 Q4 earnings on February 24 Pre-Market (EST), actual revenue USD 199.91 M (forecast USD 199.44 M), actual EPS USD -0.4654 (forecast USD -0.3842)

Apellis Pharma released FY2025 earnings on February 24 Pre-Market (EST), actual revenue USD 1.004 B (forecast USD 1.005 B), actual EPS USD 0.1724 (forecast USD 0.2576)

Apellis Pharma to Release FY2025 Q4 Earnings on February 24, 2026 Pre-Market EST, Forecast Revenue USD 199.28 M, EPS USD -0.3852

Apellis CEO Reports Sale of Common Stock

David O. Watson, General Counsel of Apellis Pharmaceuticals Inc., Disposes of Common Stock

William Blair Maintains Buy Rating on Apellis Pharmaceuticals

Sobi's Aspaveli® Receives EU Approval for Rare Kidney Diseases

Citigroup Analyst Maintains Buy Rating and Sets Target Price for Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.'s EMPAVELI® Receives FDA Approval

Geode Capital Management LLC Increases Stake in Apellis Pharmaceuticals

Apellis Pharmaceuticals General Counsel Sold Company Stock

H.C. Wainwright Analyst Maintains Buy Rating on Apellis Pharmaceuticals

Apellis Pharmaceuticals Reports Five-Year Study Results of SYFOVRE® Treatment

William Blair Maintains Buy Rating for Apellis Pharmaceuticals

Rama Recommends Apellis Pharmaceuticals Stock

Nadeau Recommends Healthcare Stocks, Mizuho Maintains Hold Rating on Apellis Pharmaceuticals

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BIIB

APLS

ARKG

LABU

IBBQ

SBIO

Biogen is expanding its focus on immunology, particularly in lupus and kidney disease, as part of its growth strategy. Adam Meyers highlighted the company's late-stage programs, including litifilimab for lupus, which shows promising Phase 2 results. The acquisition of Apellis is expected to enhance Biogen's nephrology capabilities. Meyers emphasized the need for diversification guided by scientific rationale and patient needs, with a focus on leveraging existing expertise from its multiple sclerosis business.

Market Beat

Biogen

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VG Health

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Health Care Select Sector SPDR

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Apellis Pharmaceuticals has completed its merger with Biogen, transitioning into a privately held subsidiary. As part of the merger, Apellis issued contingent value rights (CVRs) tied to future sales of its product SYFOVRE, with potential payouts up to $4.00 per CVR. The merger led to significant changes in Apellis's capital structure, including the termination of its stock purchase plan and delisting from Nasdaq. Analysts currently rate APLS stock as a Hold with a price target of $41.00, while Spark's AI Analyst gives it a Neutral rating due to mixed financial signals.

Tip Ranks

Equiniti Group Plc

Apellis Completes Biogen Merger and Goes Private

RBC Capital's Lisa Walter has maintained a Hold rating on Apellis Pharmaceuticals (APLS) with a price target of $41.00, slightly below the current share price of $41.03. Walter, a 3-star analyst, has an average return of 2.6% and a 52.63% success rate. The consensus among analysts for Apellis is also a Hold, with an average price target of $39.59.

iShares Global Healthcare

iShares US Pharma

ROYAL BANK OF CANADA

Rhythm Pharma

United Therap

RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $0.15 per share, exceeding estimates by $0.53. The company generated $268.30 million in revenue, surpassing expectations of $203.58 million. Apellis has a net margin of 2.23% and a return on equity of 8.20%. Despite the positive earnings report, shares fell 0.3% to $41.01. Analysts have mixed ratings on the stock, with a consensus price target of $34.89. The company focuses on developing therapies for rare diseases, with its lead product, Syfovre, approved for geographic atrophy.

Beam Therapeutics

Invesco

JPMorgan Chase

Barclays

Raymond James Financial

Wells Fargo

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Beats Estimates By $0.53 EPS

Earnings Watch

Apellis Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 268.3 M

Apellis Pharmaceuticals (NASDAQ:APLS) reached a new 52-week high of $41.05, closing at $40.9750 with a trading volume of 250,063 shares. Analysts have mixed ratings, with three Buy, eighteen Hold, and two Sell ratings. The company reported $0.47 EPS, exceeding estimates, but revenue declined 5.9% year-over-year. Institutional investors hold 96.29% of shares, and Apellis focuses on therapies for rare diseases, with its lead product, Syfovre, approved for geographic atrophy.

Citigroup

Bank of Nova Scottia

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High  - Here's What Happened

RVMD

TVTX

The SPDR S&P Biotech ETF (XBI) has experienced a significant outflow of approximately $291 million, marking a 3.4% decrease in shares outstanding from 63.9 million to 61.7 million. Key components include Apellis Pharmaceuticals (APLS) trading flat, Travere Therapeutics (TVTX) down 2.7%, and Revolution Medicines (RVMD) up 0.7%. XBI's 52-week range is $75.68 to $139.19, with the last trade at $135.87. This outflow may impact the underlying holdings of the ETF as units are destroyed to accommodate investor demand.

nasdaq

Revolution Medicines

Travere Therapeutics

Nasdaq

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

XBI, APLS, TVTX, RVMD: ETF Outflow Alert

CERS

AVNS

Three healthcare stocks, Avanos Medical (AVNS), Apellis Pharmaceuticals (APLS), and Cerus Corp (CERS), are showing signs of being overbought, with RSI values of 90, 86.8, and 86 respectively. AVNS has gained 78% recently due to a going-private deal, APLS surged 100% following an acquisition announcement by Biogen, and CERS reported strong Q1 results, raising its sales guidance. Investors should be cautious as these stocks may face a downturn.

benzinga_article

Cerus

Avanos Medical

Top 3 Health Care Stocks That May Collapse This Month

Apellis Pharmaceuticals has updated its Executive Separation Benefits and Retention Plan in light of its merger with Biogen. The amendment, effective upon merger closure, accelerates vesting of unvested payments for executives terminated without cause or resigning for good reason. It also revises the definition of “good reason” for C-level officers. This aims to enhance executive protections and retention incentives. Analysts rate APLS stock as a Hold with a $41.00 price target, citing weak technical momentum but improving commercial traction and solid liquidity.

Apellis Updates Executive Separation Plan Amid Biogen Merger

Apellis Pharma(APLS.US)